The Supreme Court Case Testing Mass Tort Preemption: Monsanto v. Durnell Heads to Oral Arguments

On April 1, 2026, a coalition of 18 attorneys general filed an amicus brief urging the U.S. Supreme Court to reject Monsanto's argument that federal pesticide statutes preempt state failure-to-warn claims. Oral arguments in Monsanto Co. v. Durnell (No. 24-1068) are set for April 27, with an opinion anticipated before the court's summer recess in late June.

The case reaches the court as Bayer, which acquired Monsanto for $63 billion in 2018, reports over $16 billion in cumulative defense and settlement expenses. A separate $7.25 billion class settlement in Missouri state court is pending final approval. A ruling favoring Monsanto would restrict state failure-to-warn claims across federally labeled agricultural products and influence tort actions involving other regulated substances.

Case Background: The Missouri Judgment

John Durnell applied Roundup on his Missouri property over two decades before receiving a non-Hodgkin lymphoma diagnosis. A Missouri state jury awarded him $1.25 million in compensatory damages under a strict liability failure-to-warn theory, finding that Monsanto failed to provide adequate warnings regarding the carcinogenic risks of glyphosate formulations.

The Missouri Court of Appeals affirmed the judgment. The Supreme Court granted certiorari in January 2026 on the question of whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state common-law failure-to-warn claims when the EPA has not mandated a cancer warning on the approved product label.

Statutory Preemption Analysis

FIFRA governs the registration, classification, and labeling of pesticides distributed in the United States. Registrants cannot alter EPA-approved labels without agency authorization. Monsanto contends that allowing state-court juries to impose liability for the absence of a cancer warning creates an irreconcilable conflict when the EPA has repeatedly concluded that glyphosate is not likely to be carcinogenic to humans.

The respondent and supporting state attorneys general argue that FIFRA does not bar parallel state-law duties. They cite the Supreme Court's decision in Bates v. Dow Agrosciences LLC (2005), which held that FIFRA's preemption clause (7 U.S.C. § 136v(b)) prohibits only state labeling requirements that are in addition to or different from federal requirements. Under Bates, state rules that are fully consistent with federal misbranding prohibitions survive preemption scrutiny.

Monsanto's Position

Monsanto argues that Bates did not address situations where the EPA specifically reviewed safety data and formally declined to require a warning. The company asserts that state tort verdicts imposing liability for omitting a warning directly conflict with the EPA's administrative determinations. The U.S. Solicitor General filed an amicus brief in December 2025 supporting Monsanto's position.

The State Coalition and Amici

The 18-attorney-general coalition (representing Arizona, California, Colorado, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New Mexico, New York, Oregon, Rhode Island, Vermont, and Wisconsin) argues that state common-law claims provide vital consumer remedies. Their brief asserts that manufacturers can satisfy both federal labeling obligations and state-law duties, and that preemption should not be implied absent clear congressional intent.

Amicus briefs supporting the respondent were also filed by more than 200 environmental and public health groups. Conversely, agricultural trade associations and several agricultural-state officials filed briefs in support of Monsanto.

Potential Impact on Toxic Tort Dockets

Impact on Active Roundup Caseloads

Approximately 65,000 active Roundup claims remain pending in state and federal courts, alongside the proposed $7.25 billion class resolution that received preliminary approval on March 4, 2026. The class opt-out deadline is June 4, 2026. Litigation teams evaluating whether to opt out must factor in the possibility that a broad preemption ruling could eliminate state-court failure-to-warn claims.

Broader Product Liability Implications

A broad preemption ruling could encourage defense challenges across other federally regulated product categories. Manufacturers of pharmaceuticals, medical devices, and chemical formulations could assert that federal agency approval of label text preempts state-law warning duties, altering motion practice in multi-district litigation nationwide.

Historical Verdict Context

Roundup litigation has generated substantial jury findings over the past eight years:

• Johnson v. Monsanto (2018): $289 million verdict (reduced to $20.5 million on appeal).
• Pilliod v. Monsanto (2019): $2.055 billion verdict (reduced to $87 million on appeal).
• Hardeman v. Monsanto (2019): $80.3 million verdict (reduced to $25.3 million); cert denied in 2022.

While Bayer has resolved thousands of claims through approximately $11 billion in prior settlement payments, the Durnell petition provides the Supreme Court an opportunity to rule directly on the scope of FIFRA preemption.

Evidentiary Priorities for Active Files

Strategic Implications for Failure-to-Warn Litigation

Monsanto v. Durnell represents an important test of whether federal regulatory approval shields manufacturers from state common-law liability. Regardless of the Supreme Court's ruling on preemption, plaintiff viability across chemical and toxic tort dockets depends on documented medical evidence: verified pathology reports, diagnostic staging, and treatment chronologies.

Reverse search uses insurance data to fill in treatment gaps clients don't always remember, surfacing facilities, dates, and clinicians as needed.

Records generally return in 4 days on average, with roughly 30-40% returned same-day on electronic requests. Because medical record retrieval is an itemized case disbursement, invoices flow directly onto settlement statements.

Sources: SCOTUSblog, California AG, Illinois AG, Maryland AG, JD Supra, Bayer, BeyondPesticides. Verdict figures from court records and appellate orders.